Stellar Biotech Inc (SBOTF) 0.6700 $SBOTF Stellar

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Stellar Biotech Inc (SBOTF) 0.6700 $SBOTF

Stellar Biotechnologies, Inc. (Nasdaq:SBOT) to Ring The Nasdaq Stock Market Closing Bell
GlobeNewswire - Wed Nov 04, 9:00AM CST
What:
SBOT: 2.77 (-0.10), NDAQ: 70.15 (+0.12)

Stellar Biotechnologies Announces Approval of NASDAQ Uplisting
Marketwired - Tue Nov 03, 3:15PM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , today announced that the Company has received approval for its common shares to begin trading on The NASDAQ Capital Market ("Nasdaq" .
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Announces Results of Special Meeting of Shareholders
Marketwired - Thu Oct 29, 2:04PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , announces that a Special Meeting of Shareholders was held today, October 29, 2015 (the "Meeting" , at which a proposed change to the Company's Articles (bylaws) was approved.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies and Amaran Biotechnology Provide Update on Collaboration
Marketwired - Thu Oct 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , is pleased to provide an update on the Company's ongoing collaboration with privately-held Taiwan biopharmaceuticals manufacturer Amaran Biotechnology, Inc. ("Amaran" .
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
Marketwired - Fri Aug 28, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , today announced that, subject to regulatory approval, the Company will proceed with a consolidation of its issued and outstanding common shares (the "Shares" on the basis of one (1) post-consolidated common Share for every ten (10) pre-consolidated Shares (the "Reverse Split" .
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Reports Third Quarter 2015 Financial Results and Operational Highlights
Marketwired - Mon Aug 10, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapy markets, today announced its financial results for the third fiscal quarter ended June 30, 2015.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Signs Collaboration Agreement to Expand KLH Aquaculture Operations
Marketwired - Tue Jul 28, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, today announced that the Company has entered into a collaboration agreement with Ostiones Guerrero SA de CV ("Ostiones" (the "Agreement" to secure a unique strategic site in Baja California, Mexico for the development of an additional aquaculture locale and expansion of Stellar KLH(TM) production to meet the increasing needs of its customers.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Retains The Ruth Group to Advance Communications Objectives
Marketwired - Thu Jul 09, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), a leading provider of Keyhole Limpet Hemocyanin (KLH) protein, a crucial component for the development of many novel immunotherapies, today announced that it has retained New York City-based investor and public relations agency The Ruth Group as its strategic communications advisors.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies to Present at 5thAnnual LD Micro Invitational
Marketwired - Mon Jun 01, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Stellar executives will present at the 5th Annual LD Micro Invitational Conference, being held June 1-3, 2015 at the Luxe Sunset Boulevard Hotel, Los Angeles, CA.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies to Present at 2015 Marcum MicroCap Conference
Marketwired - Wed May 27, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that Company executives will present at the 2015 Marcum MicroCap Conference, being held May 27-28, 2015 at the Grand Hyatt in New York City, NY.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies' Immunology 2015 Poster Available Online
Marketwired - Fri May 15, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced that the Company's poster presentation at this week's IMMUNOLOGY 2015 conference, the Annual Meeting of the American Association of Immunologists (AAI), has been posted to the Company's website. http://tinyurl.com/n5hq43w.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Reports Second Quarter 2015 Financial Results
Marketwired - Mon May 11, 3:30PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, today announced its financial results for the second fiscal quarter and six months ended March 31, 2015.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Presents Poster at Immunology 2015 on the Immunogenicity of Different Forms and Preparations of KLH
Marketwired - Thu Apr 30, 7:30AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) today announced the presentation of results from preclinical studies analyzing the immunogenicity of different forms and preparations of Keyhole Limpet Hemocyanin (KLH), and relating to the Company's work in developing methods to identify the appropriate functional properties of KLH for use in immunotherapy and immunodiagnostic applications.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies and Neovacs S.A. Expand KLH Supply Relationship
Marketwired - Wed Apr 01, 1:00AM CDT
Stellar Biotechnologies, Inc. ("Stellar" or the "Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) and Neovacs S.A. ("Neovacs" (ALTERNEXT PARIS: ALNEV) today announced that the Companies have entered into an expanded supply agreement to meet Neovacs' requirements for Keyhole Limpet Hemocyanin (KLH), a primary component of Neovacs' proprietary Kinoid immunotherapy technology.
KLH.VN: 5.380 (-0.230)

First FDA Breakthrough Therapy Designation for KLH-Conjugate Immunotherapy Signals Key Step for Novel Carrier Molecule
Marketwired - Tue Mar 10, 4:32PM CDT
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" is encouraged that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for a KLH-based immunotherapy compound in the treatment of adult patients with EGFRvIII-positive glioblastoma being developed by Celldex Therapeutics, Inc.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Reports First Quarter 2015 Financial Results
Marketwired - Mon Feb 09, 7:30AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, announced financial results for the first quarter period ended December 31, 2014.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies to Present at Biotech Showcase(TM) 2015 Conference
Marketwired - Thu Jan 08, 7:31AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) announced today that the Company's management team will present at the 7th Annual Biotech Showcase 2015 conference, being held at the Parc 55 Wyndham Hotel in San Francisco, CA, on Tuesday, January 13 at 2:30 p.m. PST.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies Reports Year-End 2014 Financial Results
Marketwired - Thu Nov 13, 9:17AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH), the leader in sustainable manufacture of Keyhole Limpet Hemocyanin ("KLH" , an important immune-stimulating protein used in wide-ranging immunotherapeutic markets, has reported preliminary financial results for the year ended August 31, 2014.
KLH.VN: 5.380 (-0.230)

Stellar Biotechnologies and Araclon Biotech Sign Exclusive KLH Supply Agreement for Clinical Trials in Alzheimer's Active Immunotherapies
Marketwired - Tue Nov 11, 11:46AM CST
Stellar Biotechnologies, Inc. ("Stellar" or "the Company" (OTCQB: SBOTF) (TSX VENTURE: KLH) and Araclon Biotech SL ("Araclon" today announced that the companies have executed a definitive exclusive supply agreement to meet Araclon's Phase (II and III) clinical trial requirements for Keyhole Limpet Hemocyanin (KLH) used in Araclon's active immunotherapies against Alzheimer's disease.
KLH.VN: 5.380 (-0.230)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LONGi's Four Paths to Global Green Development

Updated Category News Views 62

LONGi's Vision: A Cleaner, Greener Future Amidst the buzz at COP31 in Antalya, LONGi is making waves with promises of a cleaner future. They're not just throwing around eco-friendly slogans—this company's laying down real pathways to tackle climate change, one solar panel at a time. Aiming for Industrial Transformation LONGi's got their sights set on shaking up...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 363

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 149

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 469

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 283

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 92

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 34

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing in Kronos Worldwide: Why Now is the Time

Updated Category News Views 150

Why Kronos Worldwide is a Smart Investment Choice Kronos Worldwide, Inc. (NYSE: KRO) is poised to benefit from a rising demand for titanium dioxide (TiO2) and is experiencing less pricing pressure this year. The company's cost-saving strategies are expected to enhance profit margins, making this an excellent time to think about investing in KRO. With a promising outlook,...

Continue Reading
Old National Transforms Wealth Advisory Services for Clients

Updated Category News Views 333

Old National Unveils New Name for Wealth Advisory Division Old National Bancorp has made a notable change in its wealth advisory division by renaming Old National Investments to Old National Wealth Advisors (ONWA). This rebranding reflects the extensive range of services that the division's financial professionals offer to their clients. With a dedicated team of...

Continue Reading
Archer's Exciting Rebrand Elevates Their Meat Snack Lineup

Updated Category News Views 693

Archer Embraces a Fresh Brand Identity Fast-rising meat snack sensation, Archer, has undergone a significant transformation with a bold new brand identity that is sure to turn heads. Formerly known as Country Archer Provisions, Archer has introduced a streamlined name, a vibrant logo, and new packaging designed to enhance brand recognition and consumer engagement in a...

Continue Reading
Noveon Magnetics Secures $215 Million Investment for Growth

Updated Category News Views 290

Noveon Magnetics Secures Significant Investment to Enhance Manufacturing Noveon Magnetics, Inc., recognized as a prominent U.S. manufacturer of sintered rare earth permanent magnets, has successfully closed a remarkable $215 million Series C financing round. This initiative was led primarily by One Investment Management, who contributed $200 million. The funds will...

Continue Reading
Luckin Coffee Celebrates 30,000 Stores with New Flagship Concept

Updated Category News Views 253

Luckin Coffee Marks a Milestone with Its 30,000th Store In an impressive display of growth and innovation, Luckin Coffee, a leading retail coffee chain, has officially launched its 30,000th store, the Origin Flagship. This milestone highlights the brand's dedication to quality and sustainable practices, aimed at meeting the ever-evolving demands of coffee enthusiasts....

Continue Reading